NASDAQ:CSBR - Champions Oncology Stock Price, Price Target & More

$3.92 +0.03 (+0.77 %)
(As of 04/25/2018 10:00 AM ET)
Previous Close$4.00
Today's Range$3.92 - $3.92
52-Week Range$2.19 - $4.75
Volume275 shs
Average Volume33,721 shs
Market Capitalization$44 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.96

About Champions Oncology (NASDAQ:CSBR)

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. The company markets its products through Internet, word of mouth, and a network of sales force to patients and physicians. Champions Oncology, Inc. has collaboration agreements with The Addario Lung Cancer Medical Institute and AstraZeneca to develop cohorts of PDX models. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CSBR
CUSIPN/A
Phone201-808-8400

Debt

Debt-to-Equity RatioN/A
Current Ratio0.68%
Quick Ratio0.68%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.41 million
Price / Sales2.80
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book98.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-6,880,000.00
Net Margins-17.17%
Return on Equity-854.38%
Return on Assets-46.60%

Miscellaneous

Employees79
Outstanding Shares11,000,000

How to Become a New Pot Stock Millionaire

Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology, Inc. (NASDAQ:CSBR) released its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $5.08 million for the quarter. Champions Oncology had a negative return on equity of 854.38% and a negative net margin of 17.17%. View Champions Oncology's Earnings History.

Who are some of Champions Oncology's key competitors?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:
  • Dr. Ronnie Morris M.D., CEO & Director (Age 52)
  • Mr. David Barry Miller, Chief Financial Officer (Age 49)
  • Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 65)
  • Mr. Mark Weinstein, Chief Information Officer
  • Dr. Angela M. Davies M.D., FRCPC, Chief Medical Officer (Age 48)

Has Champions Oncology been receiving favorable news coverage?

Press coverage about CSBR stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Champions Oncology earned a daily sentiment score of 0.08 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $3.92.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $44 million and generates $15.41 million in revenue each year. Champions Oncology employs 79 workers across the globe.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]


MarketBeat Community Rating for Champions Oncology (CSBR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Champions Oncology (NASDAQ:CSBR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

Champions Oncology (NASDAQ:CSBR) Earnings History and Estimates Chart

Earnings by Quarter for Champions Oncology (NASDAQ:CSBR)

Champions Oncology (NASDAQ CSBR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018Q3 2018($0.01)$5.08 millionViewListenView Earnings Details
12/7/2017Q2 2018($0.01)$5.20 millionViewListenView Earnings Details
9/14/2017Q1 2018($0.06)$5.03 millionViewN/AView Earnings Details
7/27/2017Q4 2017($0.22)$3.72 millionViewN/AView Earnings Details
3/16/2017Q3 2017($0.13)$3.57 millionViewN/AView Earnings Details
11/29/2016Q2 2017($0.05)$4.46 millionViewN/AView Earnings Details
9/9/2016Q1 2017($0.26)$3.67 millionViewN/AView Earnings Details
7/28/2016Q4 2016($0.30)$2.84 millionViewN/AView Earnings Details
3/15/2016Q316($0.21)$1.80 million$2.60 millionViewListenView Earnings Details
12/14/2015Q2 2016($0.29)$2.97 millionViewN/AView Earnings Details
9/10/2015Q1 2016($0.33)$2.82 millionViewN/AView Earnings Details
7/28/2015Q4 2015($0.60)$3.24 millionViewN/AView Earnings Details
3/17/2015Q3 2015($0.48)$1.83 millionViewN/AView Earnings Details
12/12/2014Q2 2015($0.60)$1.88 millionViewN/AView Earnings Details
9/11/2014Q1 2015($0.60)$1.91 millionViewN/AView Earnings Details
7/24/2014Q4 2014($0.36)$2.46 millionViewN/AView Earnings Details
3/13/2014Q3 2014($0.12)$3.69 millionViewN/AView Earnings Details
12/12/2013Q1 14($0.03)$2.38 millionViewN/AView Earnings Details
9/13/2013Q1($0.02)$3.02 millionViewN/AView Earnings Details
7/26/2013Q4 2013($0.36)$1.84 millionViewN/AView Earnings Details
3/14/2013Q3 13($0.01)$2.92 millionViewN/AView Earnings Details
12/13/2012Q2 2013($0.48)ViewN/AView Earnings Details
9/12/2012Q1 2013($0.34)ViewN/AView Earnings Details
7/18/2012Q4 2012($0.72)ViewN/AView Earnings Details
3/14/2012Q3 2012($0.44)ViewN/AView Earnings Details
12/14/2011Q2 2012($0.60)ViewN/AView Earnings Details
9/13/2011Q1 2012($0.48)ViewN/AView Earnings Details
7/15/2011Q4 2011($0.84)ViewN/AView Earnings Details
3/7/2011Q3 2011($0.24)ViewN/AView Earnings Details
9/13/2010Q1 2011($0.20)ViewN/AView Earnings Details
7/28/2010Q4 2010($0.24)ViewN/AView Earnings Details
3/17/2010Q3 2010($0.28)ViewN/AView Earnings Details
12/15/2009Q2 2010($0.22)ViewN/AView Earnings Details
9/14/2009Q1 2010($0.37)ViewN/AView Earnings Details
3/18/2009Q3 2009($0.23)ViewN/AView Earnings Details
12/16/2008Q2 2009($0.12)ViewN/AView Earnings Details
9/16/2008Q1 2009($0.12)ViewN/AView Earnings Details
3/6/2008Q3 2008$0.24ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Champions Oncology (NASDAQ:CSBR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Champions Oncology (NASDAQ CSBR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.30%
Institutional Ownership Percentage: 37.85%
Insider Trading History for Champions Oncology (NASDAQ:CSBR)
Institutional Ownership by Quarter for Champions Oncology (NASDAQ:CSBR)

Champions Oncology (NASDAQ CSBR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/27/2018Ronnie MorrisCEOBuy4,535$3.59$16,280.651,114,282View SEC Filing  
3/22/2018Ronnie MorrisCEOBuy260$3.49$907.401,111,407View SEC Filing  
10/21/2016Ronnie MorrisPresidentBuy30,000$1.66$49,800.001,091,347View SEC Filing  
10/19/2016Ronnie MorrisPresidentBuy10,000$1.70$17,000.001,081,347View SEC Filing  
10/18/2016Joel AckermanCEOBuy2,000$1.70$3,400.001,043,266View SEC Filing  
10/14/2016Joel AckermanCEOBuy7,300$1.67$12,191.001,035,466View SEC Filing  
10/14/2016Ronnie MorrisPresidentBuy10,305$1.66$17,106.301,061,347View SEC Filing  
10/13/2016Ronnie MorrisPresidentBuy29,695$1.67$49,590.651,041,347View SEC Filing  
10/10/2016Ronnie MorrisPresidentBuy9,537$1.66$15,831.421,026,347View SEC Filing  
10/7/2016Joel AckermanCEOBuy8,202$1.63$13,369.261,027,764View SEC Filing  
9/23/2016Joel AckermanCEOBuy33$1.65$54.451,026,764View SEC Filing  
9/21/2016Joel AckermanCEOBuy5,000$1.66$8,300.001,022,731View SEC Filing  
9/20/2016Ronnie MorrisPresidentBuy3,000$1.58$4,740.001,021,810View SEC Filing  
3/11/2015Michael Maurice BrownMajor ShareholderBuy6,250,000$0.40$2,500,000.00View SEC Filing  
3/20/2014Daniel Newman MendelsonDirectorBuy100,000$1.08$108,000.00View SEC Filing  
3/19/2014Ronnie MorrisPresidentBuy100,000$1.07$107,000.00View SEC Filing  
1/28/2013Michael Maurice BrownMajor ShareholderBuy7,000,000$0.50$3,500,000.00View SEC Filing  
1/28/2013Ronnie MorrisPresidentBuy500,000$0.50$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Champions Oncology (NASDAQ CSBR) News Headlines

Source:
DateHeadline
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex HouseChampions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
finance.yahoo.com - April 4 at 5:32 PM
Insider Buying: Champions Oncology Inc (CSBR) CEO Acquires 4,535 Shares of StockInsider Buying: Champions Oncology Inc (CSBR) CEO Acquires 4,535 Shares of Stock
www.americanbankingnews.com - March 28 at 11:10 PM
Champions Oncology (CSBR) Issues Quarterly  Earnings ResultsChampions Oncology (CSBR) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 9:28 AM
Champions Oncology, Inc. to Host Earnings CallChampions Oncology, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 4:29 PM
Champions Oncology Reports Quarterly Revenue of $5.1 MillionChampions Oncology Reports Quarterly Revenue of $5.1 Million
finance.yahoo.com - March 15 at 4:29 PM
Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?
finance.yahoo.com - March 15 at 9:55 AM
Champions Oncology (CSBR) to Release Earnings on ThursdayChampions Oncology (CSBR) to Release Earnings on Thursday
www.americanbankingnews.com - March 8 at 8:16 PM
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018
finance.yahoo.com - March 7 at 10:12 AM
How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?
finance.yahoo.com - February 28 at 9:56 AM
Champions Oncology to Participate at the 30th Annual ROTH ConferenceChampions Oncology to Participate at the 30th Annual ROTH Conference
finance.yahoo.com - February 26 at 9:54 AM
Motivated Patients with ROS1 Cancer Initiate Global Research StudyMotivated Patients with ROS1 Cancer Initiate Global Research Study
finance.yahoo.com - February 21 at 10:25 AM
February Insights Into Healthcare Stocks: Champions Oncology Inc (NASDAQ:CSBR)February Insights Into Healthcare Stocks: Champions Oncology Inc (NASDAQ:CSBR)
finance.yahoo.com - February 15 at 9:06 AM
Why Champions Oncology Inc’s (NASDAQ:CSBR) CEO Pay Matters To YouWhy Champions Oncology Inc’s (NASDAQ:CSBR) CEO Pay Matters To You
finance.yahoo.com - December 30 at 9:07 AM
Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2018 By the Numbers : December 19, 2017Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2018 By the Numbers : December 19, 2017
finance.yahoo.com - December 19 at 5:35 PM
Blog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalet’s ARYMO ER Extended-Release Tablets C-IIBlog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalet’s ARYMO ER Extended-Release Tablets C-II
finance.yahoo.com - December 18 at 9:23 AM
Champions Oncology (CSBR) Announces  Earnings ResultsChampions Oncology (CSBR) Announces Earnings Results
www.americanbankingnews.com - December 8 at 9:28 AM
Champions Oncology Reports Record Quarterly Revenue of $5.2 MillionChampions Oncology Reports Record Quarterly Revenue of $5.2 Million
finance.yahoo.com - December 7 at 6:07 PM
Was Champions Oncology Inc’s (CSBR) Earnings Growth Better Than Industry?Was Champions Oncology Inc’s (CSBR) Earnings Growth Better Than Industry?
finance.yahoo.com - December 7 at 9:16 AM
ValuEngine Downgrades Champions Oncology (CSBR) to SellValuEngine Downgrades Champions Oncology (CSBR) to Sell
www.americanbankingnews.com - December 6 at 11:26 PM
Champions Oncology (CSBR) Set to Announce Quarterly Earnings on ThursdayChampions Oncology (CSBR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - November 30 at 1:50 AM
Champions Oncology to Announce Second Quarter Financial Results on Thursday, December 7, 2017Champions Oncology to Announce Second Quarter Financial Results on Thursday, December 7, 2017
finance.yahoo.com - November 28 at 8:35 AM
Champions Oncology Inc (CSBR): Time For A Financial Health CheckChampions Oncology Inc (CSBR): Time For A Financial Health Check
finance.yahoo.com - November 27 at 6:10 PM
Champions Oncology to Present at 10th Annual Main Event on December 5Champions Oncology to Present at 10th Annual Main Event on December 5
finance.yahoo.com - November 27 at 6:10 PM
Champions Oncology, Inc. (CSBR) Scheduled to Post Quarterly Earnings on MondayChampions Oncology, Inc. (CSBR) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 20 at 1:40 AM

SEC Filings

Champions Oncology (NASDAQ:CSBR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Champions Oncology (NASDAQ:CSBR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Champions Oncology (NASDAQ CSBR) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.